Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2934 Phase I Trial in Multiple Myeloma
NCT05646758Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2934 in multiple myeloma (MM), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity up to 18 months, Maximum Tolerated Dose up to 18 months and 3 more. Started Mar 2023; status: recruiting.
02
Drugs
TQB2934
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05646758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646758.